Tuberc Respir Dis.
2024 Jan;87(1):31-39. 10.4046/trd.2023.0085.
Recent Advances in Adjuvant Therapy for Non–Small-Cell Lung Cancer
- Affiliations
-
- 1Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
- 2Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
- KMID: 2549211
- DOI: http://doi.org/10.4046/trd.2023.0085
Abstract
- After the successful development of targeted therapy and immunotherapy for the treatment of advanced-stage non-small cell lung cancer (NSCLC), these innovative treatment options are rapidly being applied in the adjuvant setting for early-stage NSCLC. Some adjuvants that have recently been approved include osimertinib for epidermal growth factor receptor-mutated tumors and atezolizumab and pembrolizumab for selected patients with resectable NSCLC. Numerous studies on various targeted therapies and immunotherapy with or without chemotherapy are currently ongoing in the adjuvant setting. However, several questions regarding optimal strategies for adjuvant treatment remain unanswered. The present review summarizes the available literature, focusing on recent advances and ongoing trials with targeted therapy and immunotherapy in the adjuvant treatment of early-stage NSCLC.
